Alliancebernstein L.P. Purchases 146,677 Shares of Halozyme Therapeutics, Inc. $HALO

Key Points

• Alliancebernstein L.P. increased its stake in Halozyme Therapeutics by 4.8%, now owning approximately 3.2 million shares valued at $205 million.
• Insider activity includes Director Bernadette Connaughton and CEO Helen Torley selling shares, contributing to a total of 84,000 shares sold by insiders over the last quarter.
• Halozyme reported a quarterly EPS of $1.54, exceeding estimates, with a revenue increase of 40.8% year-over-year, and set guidance for FY 2025 EPS at 6.000-6.400.

Alliancebernstein L.P. grew its stake in Halozyme Therapeutics, Inc. (NASDAQ:HALO - Free Report) by 4.8% in the 1st quarter, according to its most recent 13F filing with the Securities and Exchange Commission (SEC). The institutional investor owned 3,215,109 shares of the biopharmaceutical company's stock after acquiring an additional 146,677 shares during the period. Alliancebernstein L.P. owned 2.61% of Halozyme Therapeutics worth $205,156,000 at the end of the most recent quarter.

Other institutional investors and hedge funds also recently made changes to their positions in the company. Stifel Financial Corp increased its stake in shares of Halozyme Therapeutics by 79.7% during the 4th quarter. Stifel Financial Corp now owns 30,768 shares of the biopharmaceutical company's stock worth $1,471,000 after purchasing an additional 13,647 shares during the last quarter. Hsbc Holdings PLC increased its holdings in shares of Halozyme Therapeutics by 52.0% during the 4th quarter. Hsbc Holdings PLC now owns 9,615 shares of the biopharmaceutical company's stock worth $462,000 after acquiring an additional 3,289 shares during the last quarter. AXA S.A. raised its stake in Halozyme Therapeutics by 22.1% in the 4th quarter. AXA S.A. now owns 131,891 shares of the biopharmaceutical company's stock valued at $6,306,000 after acquiring an additional 23,835 shares during the period. Algert Global LLC bought a new stake in Halozyme Therapeutics in the 4th quarter valued at $521,000. Finally, Baird Financial Group Inc. lifted its holdings in Halozyme Therapeutics by 2.0% during the 4th quarter. Baird Financial Group Inc. now owns 11,119 shares of the biopharmaceutical company's stock valued at $532,000 after purchasing an additional 221 shares during the last quarter. Institutional investors own 97.79% of the company's stock.

Insiders Place Their Bets

In other news, CEO Helen Torley sold 20,000 shares of the stock in a transaction dated Wednesday, September 3rd. The stock was sold at an average price of $74.44, for a total transaction of $1,488,800.00. Following the transaction, the chief executive officer directly owned 733,719 shares in the company, valued at approximately $54,618,042.36. This represents a 2.65% decrease in their position. The sale was disclosed in a document filed with the Securities & Exchange Commission, which can be accessed through this link. Also, Director Bernadette Connaughton sold 4,000 shares of Halozyme Therapeutics stock in a transaction that occurred on Tuesday, September 2nd. The stock was sold at an average price of $73.68, for a total value of $294,720.00. Following the completion of the transaction, the director directly owned 46,952 shares in the company, valued at $3,459,423.36. This trade represents a 7.85% decrease in their ownership of the stock. The disclosure for this sale can be found here. Insiders have sold a total of 104,000 shares of company stock valued at $6,316,120 over the last ninety days. 2.90% of the stock is currently owned by insiders.

Halozyme Therapeutics Stock Down 0.2%

NASDAQ:HALO traded down $0.18 on Tuesday, hitting $75.67. The stock had a trading volume of 594,250 shares, compared to its average volume of 1,966,201. Halozyme Therapeutics, Inc. has a 52 week low of $42.01 and a 52 week high of $76.28. The business's fifty day moving average is $63.28 and its 200 day moving average is $59.97. The company has a quick ratio of 7.01, a current ratio of 8.36 and a debt-to-equity ratio of 4.54. The company has a market cap of $8.85 billion, a PE ratio of 17.31, a P/E/G ratio of 0.41 and a beta of 1.19.

Halozyme Therapeutics (NASDAQ:HALO - Get Free Report) last issued its quarterly earnings data on Tuesday, August 5th. The biopharmaceutical company reported $1.54 EPS for the quarter, topping the consensus estimate of $1.23 by $0.31. Halozyme Therapeutics had a return on equity of 150.85% and a net margin of 47.28%.The firm had revenue of $325.72 million during the quarter, compared to the consensus estimate of $282.66 million. During the same period in the prior year, the business posted $0.91 earnings per share. The company's quarterly revenue was up 40.8% compared to the same quarter last year. Halozyme Therapeutics has set its FY 2025 guidance at 6.000-6.400 EPS. On average, equities research analysts expect that Halozyme Therapeutics, Inc. will post 4.73 EPS for the current fiscal year.

Wall Street Analysts Forecast Growth

Several equities analysts have commented on HALO shares. Morgan Stanley upped their price objective on shares of Halozyme Therapeutics from $75.00 to $80.00 and gave the company an "overweight" rating in a report on Monday, August 18th. HC Wainwright upped their price target on shares of Halozyme Therapeutics from $72.00 to $75.00 and gave the company a "buy" rating in a research note on Wednesday, August 6th. Wall Street Zen cut shares of Halozyme Therapeutics from a "strong-buy" rating to a "buy" rating in a report on Friday. JPMorgan Chase & Co. raised their price objective on shares of Halozyme Therapeutics from $60.00 to $63.00 and gave the stock a "neutral" rating in a research report on Thursday, August 7th. Finally, Zacks Research upgraded shares of Halozyme Therapeutics from a "hold" rating to a "strong-buy" rating in a research report on Tuesday, September 2nd. One analyst has rated the stock with a Strong Buy rating, four have issued a Buy rating, five have issued a Hold rating and two have issued a Sell rating to the stock. Based on data from MarketBeat, Halozyme Therapeutics currently has a consensus rating of "Hold" and an average price target of $67.11.

Halozyme Therapeutics Company Profile

Halozyme Therapeutics, Inc, a biopharma technology platform company, researches, develops, and commercializes proprietary enzymes and devices in the United States, Switzerland, Belgium, Japan, and internationally. The company's products are based on the patented recombinant human hyaluronidase enzyme (rHuPH20) that enables delivery of injectable biologics, such as monoclonal antibodies and other therapeutic molecules, as well as small molecules and fluids.